The impact of PET and SPECT on dosimetry for targeted radionuclide therapy.
about
Therapeutic radionuclides in nuclear medicine: current and future prospectsPrediction of therapy tumor-absorbed dose estimates in I-131 radioimmunotherapy using tracer data via a mixed-model fit to time activityIn vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT.Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct Monte Carlo methods.Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".Comparison of Diagnostic Sensitivity and Quantitative Indices Between (68)Ga-DOTATOC PET/CT and (111)In-Pentetreotide SPECT/CT in Neuroendocrine Tumors: a Preliminary Report.Strengths and Weaknesses of a Planar Whole-Body Method of (153)Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry.MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapySubacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.A no-gold-standard technique for objective assessment of quantitative nuclear-medicine imaging methods.Toward an organ based dose prescription method for the improved accuracy of murine dose in orthovoltage x-ray irradiators.Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies.Absolute quantification in SPECT.Dual-Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy.A gamma camera count rate saturation correction method for whole-body planar imaging.Impact of respiratory motion and acquisition settings on SPECT liver dosimetry for radioembolization.Re-thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals.Comparison of different dosimetric methods for red marrow absorbed dose calculation in thyroid cancer therapy.Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts.Performance comparison of two commercial BGO-based PET/CT scanners using NEMA NU 2-2001.Strategies for CT tissue segmentation for Monte Carlo calculations in nuclear medicine dosimetry.Discrete beta dose kernel matrices for nuclides applied in targeted radionuclide therapy (TRT) calculated with MCNP5.Development of patient-specific molecular imaging phantoms using a 3D printer.Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres.Inter-comparison of quantitative imaging of lutetium-177 (Lu) in European hospitals
P2860
Q26861998-38B6F6B5-AD50-423C-B211-CAE0BDF8790DQ30561088-81F575F5-E281-4C4E-B268-5471E3A7227CQ33649303-3A4E1C38-4B0F-4279-BBB8-DF04BDC4239CQ33768719-845927D6-04EB-4B30-9518-1012C14EFE82Q33790290-E2800F03-6E22-4342-8466-48BDEC158239Q35880923-38804B9E-B5A7-4BA3-9CE9-706C41120955Q36241229-1F7049FF-691C-4D29-985A-D99B9EF95CF8Q36297804-D4651ABE-79D6-4098-AB0E-605D0704A6E1Q36302205-09980F97-E8E2-4928-94EB-3D4EE3CB4B0FQ36516035-E48659F9-C936-46EB-B993-BF1927A66FF4Q37038483-4330FC45-7470-4551-ABA0-F5A9BE0456D2Q37704471-A3A473F8-9259-4FF0-B19E-F4877E9647E2Q37864159-5F213228-F2D0-45B8-98A2-D891450B65F5Q37864163-B7D80831-097C-4B48-8B52-EB85C28787B5Q38612027-F3919B4B-9430-4AD6-92E0-4F55A95082FBQ39774521-FA7C7148-DC78-4389-B456-3AB1A49389CFQ40489091-BBF3FF15-A73C-4D7A-942D-9C8A87B7728DQ47588415-A481FF05-E925-43B3-B61D-C16CACBE3BD0Q50536307-6B4A2181-1D7E-499D-8B34-E21D4FA14DA7Q50545742-51A3993A-E89D-4A19-8CBE-AB908FE156C1Q50918279-9B86652F-1701-4563-8243-08EE078567ABQ51089901-317E5373-D09B-45FD-9066-0B33BD6A7FB4Q51768811-C323B260-638D-4320-8B10-2513551A2CC7Q53057838-2317B610-851D-4478-BBBF-A9588D3F5841Q53298239-4E5491D0-BB95-446A-A633-AF6FAFB9748FQ58803949-AA3A41E2-4AC3-4422-8504-D0F9BCD595EB
P2860
The impact of PET and SPECT on dosimetry for targeted radionuclide therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The impact of PET and SPECT on dosimetry for targeted radionuclide therapy.
@ast
The impact of PET and SPECT on dosimetry for targeted radionuclide therapy.
@en
type
label
The impact of PET and SPECT on dosimetry for targeted radionuclide therapy.
@ast
The impact of PET and SPECT on dosimetry for targeted radionuclide therapy.
@en
prefLabel
The impact of PET and SPECT on dosimetry for targeted radionuclide therapy.
@ast
The impact of PET and SPECT on dosimetry for targeted radionuclide therapy.
@en
P2093
P356
P1476
The impact of PET and SPECT on dosimetry for targeted radionuclide therapy.
@en
P2093
EANM Dosimetry Committee
Glenn Flux
Manuel Bardies
Michael Lassmann
Myriam Monsieurs
Sauli Savolainen
Sven-Erik Strands
P356
10.1078/0939-3889-00291
P577
2006-01-01T00:00:00Z